Loading...

Hong Kong Life Sciences and Technologies Group

SEHK:8085
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
8085
SEHK
HK$57M
Market Cap
  1. Home
  2. HK
  3. Capital Goods
Company description

Hong Kong Life Sciences and Technologies Group Limited, an investment holding company, engages in anti-aging and stem cell technology, trading, money lending, and securities investment businesses in the People’s Republic of China. The last earnings update was 25 days ago. More info.


Add to Portfolio Compare Print
  • Hong Kong Life Sciences and Technologies Group has significant price volatility in the past 3 months.
8085 Share Price and Events
7 Day Returns
0%
SEHK:8085
1.6%
HK Trade Distributors
1%
HK Market
1 Year Returns
-80%
SEHK:8085
1.1%
HK Trade Distributors
-4.7%
HK Market
8085 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Hong Kong Life Sciences and Technologies Group (8085) 0% 0% -33.3% -80% -92.9% -94.9%
HK Trade Distributors 1.6% 2.6% -7.3% 1.1% -24.1% -52.9%
HK Market 1% 3.9% -7.8% -4.7% 17.5% 2%
1 Year Return vs Industry and Market
  • 8085 underperformed the Trade Distributors industry which returned 1.1% over the past year.
  • 8085 underperformed the Market in Hong Kong which returned -4.7% over the past year.
Price Volatility
8085
Industry
5yr Volatility vs Market

Value

 Is Hong Kong Life Sciences and Technologies Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Hong Kong Life Sciences and Technologies Group. This is due to cash flow or dividend data being unavailable. The share price is HK$0.01.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Hong Kong Life Sciences and Technologies Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Hong Kong Life Sciences and Technologies Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SEHK:8085 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in HKD HK$0.00
SEHK:8085 Share Price ** SEHK (2019-07-04) in HKD HK$0.01
Hong Kong Trade Distributors Industry PE Ratio Median Figure of 30 Publicly-Listed Trade Distributors Companies 10.42x
Hong Kong Market PE Ratio Median Figure of 1,510 Publicly-Listed Companies 10.82x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Hong Kong Life Sciences and Technologies Group.

SEHK:8085 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SEHK:8085 Share Price ÷ EPS (both in HKD)

= 0.01 ÷ 0.00

-2.45x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Hong Kong Life Sciences and Technologies Group is loss making, we can't compare its value to the HK Trade Distributors industry average.
  • Hong Kong Life Sciences and Technologies Group is loss making, we can't compare the value of its earnings to the Hong Kong market.
Price based on expected Growth
Does Hong Kong Life Sciences and Technologies Group's expected growth come at a high price?
Raw Data
SEHK:8085 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.45x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Global Trade Distributors Industry PEG Ratio Median Figure of 80 Publicly-Listed Trade Distributors Companies 1.17x
Hong Kong Market PEG Ratio Median Figure of 479 Publicly-Listed Companies 0.8x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Hong Kong Life Sciences and Technologies Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Hong Kong Life Sciences and Technologies Group's assets?
Raw Data
SEHK:8085 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in HKD HK$0.05
SEHK:8085 Share Price * SEHK (2019-07-04) in HKD HK$0.01
Hong Kong Trade Distributors Industry PB Ratio Median Figure of 59 Publicly-Listed Trade Distributors Companies 0.79x
Hong Kong Market PB Ratio Median Figure of 2,197 Publicly-Listed Companies 0.92x
SEHK:8085 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SEHK:8085 Share Price ÷ Book Value per Share (both in HKD)

= 0.01 ÷ 0.05

0.19x

* Primary Listing of Hong Kong Life Sciences and Technologies Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Hong Kong Life Sciences and Technologies Group is good value based on assets compared to the HK Trade Distributors industry average.
X
Value checks
We assess Hong Kong Life Sciences and Technologies Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Trade Distributors industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Trade Distributors industry average (and greater than 0)? (1 check)
  5. Hong Kong Life Sciences and Technologies Group has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Hong Kong Life Sciences and Technologies Group expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hong Kong Life Sciences and Technologies Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
9.7%
Expected Trade Distributors industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Hong Kong Life Sciences and Technologies Group expected to grow at an attractive rate?
  • Unable to compare Hong Kong Life Sciences and Technologies Group's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Hong Kong Life Sciences and Technologies Group's earnings growth to the Hong Kong market average as no estimate data is available.
  • Unable to compare Hong Kong Life Sciences and Technologies Group's revenue growth to the Hong Kong market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
SEHK:8085 Future Growth Rates Data Sources
Data Point Source Value (per year)
Hong Kong Trade Distributors Industry Earnings Growth Rate Market Cap Weighted Average 9.7%
Asia Trade Distributors Industry Revenue Growth Rate Market Cap Weighted Average 12%
Hong Kong Market Earnings Growth Rate Market Cap Weighted Average -5.2%
Hong Kong Market Revenue Growth Rate Market Cap Weighted Average 13.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SEHK:8085 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in HKD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SEHK:8085 Future Estimates Data
Date (Data in HKD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
SEHK:8085 Past Financials Data
Date (Data in HKD Millions) Revenue Cash Flow Net Income *
2019-03-31 99 -10 -23
2018-12-31 104 -79
2018-09-30 66 -10 -78
2018-06-30 103 -77
2018-03-31 140 -45 -82
2017-12-31 137 -66
2017-09-30 175 -15 -63
2017-06-30 176 -62
2017-03-31 154 -9 -65
2016-12-31 139 -32
2016-09-30 125 -96 -40
2016-06-30 137 -39

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Hong Kong Life Sciences and Technologies Group is high growth as no earnings estimate data is available.
  • Unable to determine if Hong Kong Life Sciences and Technologies Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SEHK:8085 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Hong Kong Life Sciences and Technologies Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SEHK:8085 Future Estimates Data
Date (Data in HKD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
SEHK:8085 Past Financials Data
Date (Data in HKD Millions) EPS *
2019-03-31 0.00
2018-12-31 -0.01
2018-09-30 -0.01
2018-06-30 -0.01
2018-03-31 -0.01
2017-12-31 -0.01
2017-09-30 -0.01
2017-06-30 -0.01
2017-03-31 -0.01
2016-12-31 -0.01
2016-09-30 -0.01
2016-06-30 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Hong Kong Life Sciences and Technologies Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Hong Kong Life Sciences and Technologies Group's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Hong Kong Life Sciences and Technologies Group's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Capital Goods companies here
  3. Hong Kong Life Sciences and Technologies Group's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Hong Kong Life Sciences and Technologies Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Hong Kong market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Asia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Hong Kong Life Sciences and Technologies Group has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Hong Kong Life Sciences and Technologies Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Hong Kong Life Sciences and Technologies Group's growth in the last year to its industry (Trade Distributors).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Hong Kong Life Sciences and Technologies Group does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Hong Kong Life Sciences and Technologies Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Hong Kong Life Sciences and Technologies Group's 1-year growth to the HK Trade Distributors industry average as it is not currently profitable.
Earnings and Revenue History
Hong Kong Life Sciences and Technologies Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Hong Kong Life Sciences and Technologies Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SEHK:8085 Past Revenue, Cash Flow and Net Income Data
Date (Data in HKD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 99.36 -23.24 34.25
2018-12-31 103.70 -78.74 33.08
2018-09-30 66.28 -77.74 33.38
2018-06-30 103.44 -76.84 34.52
2018-03-31 140.21 -82.20 35.96
2017-12-31 136.94 -65.86 37.76 9.50
2017-09-30 175.36 -63.15 39.59 9.50
2017-06-30 176.19 -62.39 39.77 9.50
2017-03-31 153.57 -64.71 41.13 9.50
2016-12-31 139.48 -31.97 40.38
2016-09-30 125.48 -39.66 41.45
2016-06-30 136.78 -39.14 44.49
2016-03-31 123.37 -36.50 44.87
2015-12-31 136.99 -20.92 48.39
2015-09-30 115.23 -28.46 53.79
2015-06-30 90.61 -49.16 59.06
2015-03-31 320.08 -71.46 65.37
2014-12-31 822.11 -166.69 73.38
2014-09-30 916.40 -163.34 76.78
2014-06-30 886.58 -118.90 76.41
2014-03-31 679.89 -100.08 74.24
2013-12-31 151.96 13.11 69.59
2013-09-30 57.58 30.63 62.88
2013-06-30 64.34 -34.05 59.10
2013-03-31 39.15 -34.30 49.12
2012-12-31 41.42 -42.20 36.03
2012-09-30 49.50 -48.02 29.46

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Hong Kong Life Sciences and Technologies Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Hong Kong Life Sciences and Technologies Group has efficiently used its assets last year compared to the HK Trade Distributors industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Hong Kong Life Sciences and Technologies Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Hong Kong Life Sciences and Technologies Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Trade Distributors industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Hong Kong Life Sciences and Technologies Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Hong Kong Life Sciences and Technologies Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Hong Kong Life Sciences and Technologies Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Hong Kong Life Sciences and Technologies Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Hong Kong Life Sciences and Technologies Group has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Hong Kong Life Sciences and Technologies Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Hong Kong Life Sciences and Technologies Group has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Hong Kong Life Sciences and Technologies Group Company Filings, last reported 3 months ago.

SEHK:8085 Past Debt and Equity Data
Date (Data in HKD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 251.66 0.00 85.61
2018-12-31 287.18 0.00 103.58
2018-09-30 287.18 0.00 103.58
2018-06-30 289.16 0.00 104.65
2018-03-31 289.16 0.00 104.65
2017-12-31
2017-09-30 368.39 0.00 112.71
2017-06-30 368.29 0.00 150.54
2017-03-31 368.29 0.00 150.54
2016-12-31
2016-09-30 311.68 0.00 26.73
2016-06-30 318.60 0.00 67.57
2016-03-31 318.60 0.00 67.57
2015-12-31
2015-09-30 258.47 0.00 37.64
2015-06-30 264.32 0.00 57.90
2015-03-31 264.32 0.00 57.90
2014-12-31
2014-09-30 298.30 0.00 106.05
2014-06-30 346.86 0.00 127.40
2014-03-31 346.86 0.00 127.40
2013-12-31
2013-09-30 501.34 0.00 199.35
2013-06-30 464.00 35.91 109.45
2013-03-31 464.00 35.91 109.45
2012-12-31
2012-09-30 457.57 18.34 240.30
  • Hong Kong Life Sciences and Technologies Group has no debt.
  • Hong Kong Life Sciences and Technologies Group had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Hong Kong Life Sciences and Technologies Group has sufficient cash runway for more than 3 years based on current free cash flow.
  • Hong Kong Life Sciences and Technologies Group has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -59.1% each year.
X
Financial health checks
We assess Hong Kong Life Sciences and Technologies Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Hong Kong Life Sciences and Technologies Group has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Hong Kong Life Sciences and Technologies Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Hong Kong Life Sciences and Technologies Group dividends.
If you bought HK$2,000 of Hong Kong Life Sciences and Technologies Group shares you are expected to receive HK$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Hong Kong Life Sciences and Technologies Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Hong Kong Life Sciences and Technologies Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SEHK:8085 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Hong Kong Trade Distributors Industry Average Dividend Yield Market Cap Weighted Average of 12 Stocks 4.7%
Hong Kong Market Average Dividend Yield Market Cap Weighted Average of 978 Stocks 3.6%
Hong Kong Minimum Threshold Dividend Yield 10th Percentile 1.2%
Hong Kong Bottom 25% Dividend Yield 25th Percentile 2.1%
Hong Kong Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SEHK:8085 Future Dividends Estimate Data
Date (Data in HK$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Hong Kong Life Sciences and Technologies Group has not reported any payouts.
  • Unable to verify if Hong Kong Life Sciences and Technologies Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Hong Kong Life Sciences and Technologies Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Hong Kong Life Sciences and Technologies Group has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Hong Kong Life Sciences and Technologies Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Hong Kong Life Sciences and Technologies Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Hong Kong Life Sciences and Technologies Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Hong Kong Life Sciences and Technologies Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Zhiqiang Lu
COMPENSATION HK$1,718,000
AGE 44
TENURE AS CEO 7.8 years
CEO Bio

Mr. Zhiqiang Lu has been the Chief Executive Officer of Hong Kong Life Sciences and Technologies Group Limited (formerly known as New Chinese Medicine Holdings Ltd) since September 30, 2011 and its Compliance Officer since December 1, 2012. Mr. Lu serves as an Executive Director of Global Energy Resources International Group Limited. Mr. Lu has been Executive Director at Extrawell Pharmaceutical Holdings Limited since January 27, 2017. He has been an Executive Director of Hong Kong Life Sciences and Technologies Group Limited since September 30, 2011. He served as Managing Director of Chin Mining Investment Co., Ltd. He served as the Regional Chairman of Shenzhen Lions Club. He served as a Non Executive Director of Lamtex Holdings Limited since October 29, 2014 until July 9, 2015. He served as an Executive Director of Global Energy Resources International Group Limited from November 28, 2014 to September 2, 2016. Mr. Lu holds Master of Science Degree from the International Purchasing & Supply Chain Management from Audencia NANTES. Ecole de Management, a Master of Business Administration Degree from Central State University of the United Sates of America, a Bachelor Degree in Engineering and a Bachelor Degree in Industry from Nanchang Hangkong University.

CEO Compensation
  • Zhiqiang's compensation has increased whilst company is loss making.
  • Zhiqiang's remuneration is about average for companies of similar size in Hong Kong.
Management Team Tenure

Average tenure and age of the Hong Kong Life Sciences and Technologies Group management team in years:

0.8
Average Tenure
52
Average Age
  • The average tenure for the Hong Kong Life Sciences and Technologies Group management team is less than 2 years, this suggests a new team.
Management Team

Zhiqiang Lu

TITLE
CEO, Compliance Officer & Executive Director
COMPENSATION
HK$2M
AGE
44
TENURE
7.8 yrs

Kwong Kau Chui

TITLE
Executive Director
COMPENSATION
HK$721K
AGE
52

James Zhang

TITLE
Executive Director
COMPENSATION
HK$357K
AGE
54
TENURE
0.8 yrs

Yu Sun

TITLE
Executive Director
COMPENSATION
HK$552K
AGE
47

Karen Cheung

TITLE
Executive Director
COMPENSATION
HK$292K
AGE
52
TENURE
0.8 yrs

Ngai Cheung Lau

TITLE
Executive Director
COMPENSATION
HK$104K
AGE
53
TENURE
0.5 yrs

Pauline Wong

TITLE
Company Secretary
TENURE
0.2 yrs
Board of Directors Tenure

Average tenure and age of the Hong Kong Life Sciences and Technologies Group board of directors in years:

2
Average Tenure
52
Average Age
  • The average tenure for the Hong Kong Life Sciences and Technologies Group board of directors is less than 3 years, this suggests a new board.
Board of Directors

Zhiqiang Lu

TITLE
CEO, Compliance Officer & Executive Director
COMPENSATION
HK$2M
AGE
44
TENURE
7.8 yrs

Kwong Kau Chui

TITLE
Executive Director
COMPENSATION
HK$721K
AGE
52
TENURE
9.8 yrs

James Zhang

TITLE
Executive Director
COMPENSATION
HK$357K
AGE
54
TENURE
2 yrs

Yu Sun

TITLE
Executive Director
COMPENSATION
HK$552K
AGE
47
TENURE
1.9 yrs

Karen Cheung

TITLE
Executive Director
COMPENSATION
HK$292K
AGE
52
TENURE
0.8 yrs

Ngai Cheung Lau

TITLE
Executive Director
COMPENSATION
HK$104K
AGE
53
TENURE
0.5 yrs

Yat Ming Hung

TITLE
Independent Non-Executive Director
COMPENSATION
HK$132K
AGE
67
TENURE
6.3 yrs

Yun Hing Chan

TITLE
Independent Non-Executive Director
COMPENSATION
HK$132K
AGE
71
TENURE
6.8 yrs

Hua Tang

TITLE
Independent Non-Executive Director
COMPENSATION
HK$68K
AGE
48
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (HK$) Value (HK$)
10. Aug 18 Sell Sheng Yuan Asset Management Limited Company 08. Aug 18 08. Aug 18 -232,600,000 HK$0.02 HK$-4,651,992
X
Management checks
We assess Hong Kong Life Sciences and Technologies Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Hong Kong Life Sciences and Technologies Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Could Hong Kong Life Sciences and Technologies Group Limited's (HKG:8085) Investor Composition Influence The Stock Price?

The big shareholder groups in Hong Kong Life Sciences and Technologies Group Limited (HKG:8085) have power over the company. … See our latest analysis for Hong Kong Life Sciences and Technologies Group SEHK:8085 Ownership Summary, June 5th 2019 What Does The Institutional Ownership Tell Us About Hong Kong Life Sciences and Technologies Group? … Insider Ownership Of Hong Kong Life Sciences and Technologies Group The definition of an insider can differ slightly between different countries, but members of the board of directors always count.

Simply Wall St -

How Should Investors Feel About Hong Kong Life Sciences and Technologies Group Limited's (HKG:8085) CEO Pay?

Zhiqiang Lu became the CEO of Hong Kong Life Sciences and Technologies Group Limited (HKG:8085) in 2011. … Check out our latest analysis for Hong Kong Life Sciences and Technologies Group? … According to our data, Hong Kong Life Sciences and Technologies Group Limited has a market capitalization of HK$91m, and pays its CEO total annual compensation worth HK$557k.

Simply Wall St -

Do Institutions Own Hong Kong Life Sciences and Technologies Group Limited (HKG:8085) Shares?

Every investor in Hong Kong Life Sciences and Technologies Group Limited (HKG:8085) should be aware of the most powerful shareholder groups. … Generally speaking, as a company grows, institutions will increase their ownership. … Hong Kong Life Sciences and Technologies Group is a smaller company with a market capitalization of HK$182m, so it may still be flying under the radar of many institutional investors.

Simply Wall St -

How Much Did Hong Kong Life Sciences and Technologies Group Limited's (HKG:8085) CEO Pocket Last Year?

Zhiqiang Lu became the CEO of Hong Kong Life Sciences and Technologies Group Limited (HKG:8085) in 2011. … First, this article will compare CEO compensation with compensation at similar sized companies. … See our latest analysis for Hong Kong Life Sciences and Technologies Group?

Simply Wall St -

What does Hong Kong Life Sciences and Technologies Group Limited's (HKG:8085) Balance Sheet Tell Us About Its Future?

The direct benefit for Hong Kong Life Sciences and Technologies Group Limited (HKG:8085), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is financial flexibility worth the lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

Are Insiders Buying Hong Kong Life Sciences and Technologies Group Limited (HKG:8085) Stock?

So before you buy or sell Hong Kong Life Sciences and Technologies Group Limited (HKG:8085), you may well want to know whether insiders have been buying or selling. … Check out our latest analysis for Hong Kong Life Sciences and Technologies Group. … The Last 12 Months Of Insider Transactions At Hong Kong Life Sciences and Technologies Group.

Simply Wall St -

Does Hong Kong Life Sciences and Technologies Group Limited (HKG:8085) Have A Particularly Volatile Share Price?

Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. … In comparison a stock with a beta of over one tends to be move in a similar direction to the market in the long term, but with greater changes in price.

Simply Wall St -

Is Hong Kong Life Sciences and Technologies Group Limited's (HKG:8085) CEO Pay Justified?

In 2011 Zhiqiang Lu was appointed CEO of Hong Kong Life Sciences and Technologies Group Limited (HKG:8085). … Check out our latest analysis for Hong Kong Life Sciences and Technologies Group? … According to our data, Hong Kong Life Sciences and Technologies Group Limited has a market capitalization of HK$267m, and pays its CEO total annual compensation worth HK$557k.

Simply Wall St -

Is Hong Kong Life Sciences and Technologies Group Limited's (HKG:8085) Balance Sheet Strong Enough To Weather A Storm?

Hong Kong Life Sciences and Technologies Group Limited (HKG:8085), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … Is 8085 growing fast enough to value financial flexibility over lower cost of capital … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.

Simply Wall St -

Should You Be Holding Hong Kong Life Sciences and Technologies Group Limited (HKG:8085) Right Now?

A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … Based on this beta value, 8085 appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market. … I examine 8085’s ratio of fixed assets to total assets to see whether the company is highly exposed to the risk of this type of constraint.

Simply Wall St -

Company Info

Description

Hong Kong Life Sciences and Technologies Group Limited, an investment holding company, engages in anti-aging and stem cell technology, trading, money lending, and securities investment businesses in the People’s Republic of China. The company provides anti-aging, health check and beauty, and stem cell anti-aging application related services, as well as stem cell storage and processing services; and distributes biomedical and life science products. It also leases anti-aging service platform; trades in electronic components and healthcare products; provides secured and unsecured loans to individuals and corporate customers; and trades and invests in securities. The company was formerly known as ZMAY Holdings Limited and changed its name to Hong Kong Life Sciences and Technologies Group Limited in October 2012. Hong Kong Life Sciences and Technologies Group Limited was incorporated in 2000 and is based in Central, Hong Kong.

Details
Name: Hong Kong Life Sciences and Technologies Group Limited
8085
Exchange: SEHK
Founded: 2000
HK$56,883,968
5,688,396,805
Website: http://www.hklifesciences.com
Address: Hong Kong Life Sciences and Technologies Group Limited
West Tower,
Unit 2704, 27th Floor,
Central,
Hong Kong
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SEHK 8085 Ordinary Shares The Stock Exchange of Hong Kong Ltd. HK HKD 07. Mar 2002
Number of employees
Current staff
Staff numbers
39
Hong Kong Life Sciences and Technologies Group employees.
Industry
Trading Companies and Distributors
Capital Goods
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/18 12:53
End of day share price update: 2019/07/04 00:00
Last estimates confirmation: 2018/06/26
Last earnings filing: 2019/06/23
Last earnings reported: 2019/03/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.